Search

Find out when to consult a doctor for a bad headache.

… Monday, June 20, 2022 Summary MSK neuro-oncologist Lauren Schaff discusses when to see a doctor for a headache. Updated June 20, 2022 A bad headache can be a frightening experience. But sometimes, even scarier than the pounding in your head can be the tricks your mind plays on you as it’s happening.

The American Heart Association recently issued a statement about the risk of cardiovascular disease for women with breast cancer.

… Thursday, February 1, 2018 Summary The medications that some women take for breast cancer treatment may cause heart problems. Here, we break down what these women should know. The American Heart Association recently issued a statement about the dangers of heart problems in women treated for breast cancer

Meet the Stuart family and learn why they want to revolutionize cancer treatment for people ages 15 to 39 and meet their very specific and often unmet needs.

… Friday, October 1, 2021 VIDEO | 03:15 A Gift for Life Meet the Stuart family and learn about their transformational gift to launch the Lisa and Scott Stuart Center for Adolescent and Young Adult Cancers at MSK. Video Details If you ask Scott Stuart, he will tell you that Memorial Sloan Kettering Cancer

Two second-year students -- Ellen Hukkelhoven and John Halliday -- were named Grayer Fellows for the 2010-2011 year.

… Saturday, May 1, 2010 Two second-year students were named Grayer Fellows for the 2010-2011 year. They are Ellen Hukkelhoven and John Halliday. These fellowships were established by Mr. and Mrs. Jonathan Grayer. Mr. Grayer is a member of the Gerstner Sloan Kettering Board of Trustees and the former chairman

An inherited mutation that contributes to lung cancer spread could be a target for therapies.

… Thursday, November 3, 2022 An inherited mutation in a gene called BRMS1 promotes lung cancer lung cancer metastasis.   The mutation could be targeted with therapies that prevent metastasis. Lung cancer is the leading cause of cancer death in the United States. The primary reason the disease is so deadly

Maria Jasin, PhD, a molecular biologist at the Sloan Kettering Institute, was named a recipient of the Shaw Prize in Life Science and Medicine. Dr. Jasin was recognized for her contributions to research showing that localized double-strand breaks in DNA stimulate recombination in mammalian cells.

… Tuesday, May 21, 2019 Maria Jasin, PhD , a molecular biologist at the Sloan Kettering Institute , was named a recipient of the Shaw Prize in Life Science and Medicine . Dr. Jasin was recognized for her contributions to research showing that localized double-strand breaks in DNA stimulate recombination

MSK physicians and scientists highlighted some of the institution’s latest advances in transplantation and cellular therapies at the Tandem Meetings held February 4 to 6, 2026, in Salt Lake City.

… Monday, April 6, 2026 Memorial Sloan Kettering Cancer Center (MSK) physicians and scientists highlighted some of the institution’s latest advances in transplantation and cellular therapies at the  Tandem Meetings held February 4 to 6, 2026, in Salt Lake City. The meetings, jointly hosted by the American

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

… Tuesday, August 17, 2021 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Craig Thompson Recognized in City & State’s Life Sciences Power 50 Craig B. Thompson Craig Thompson, MD , President and CEO, was named on the inaugural City & State Life Sciences Power

Scientists are using a molecule from the immune system to combat this serious complication in a new way.

… Friday, January 15, 2016 Summary Graft-versus-host disease (GVHD) is a complication of blood and marrow stem cell transplantation . A new study reveals how the patient’s immune system restores the intestinal lining following damage from GVHD and points to a strategy for a potential therapy to alleviate

Mammography has shortcomings but the price is reasonable; MRI is more effective but expensive. Two new modalities — contrast-enhanced digital mammography (CEDM) and abbreviated breast MRI (AB-MRI) — may provide the best of both.

… Thursday, June 23, 2016 Since the mid-1980s, mammography has been the primary screening modality for breast cancer. While it has reduced mortality rates, there are some notable drawbacks. Mammography fails to detect as many as 30 percent of cancers because overlying normal breast tissue obscures them